Drugs / ART6043
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05898399 | Jun 2023 → Jun 2028 expected | metastatic neoplasm, neoplasm | Artios Pharma Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ART6043 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05898399 ↗ |
| Action | Inhibit | “ART6043 inhibits Polθ with low nM potency” PMID 42440368 ↗ Jul 2026 |
| Modality | Small molecule | “ART6043, a potent, selective, allosteric, small molecule inhibitor of the polymerase function of Polθ” PMID 42440368 ↗ Jul 2026 |
| Route | Oral | “ART6043 will be given orally.” NCT05898399 ↗ |